Experts in dermatology delve into patient communication regarding treatment expectations, emphasizing the significance of ongoing follow-up and maintenance practices. They also address the safety, tolerability, and comfortability aspects associated with the use of this novel TYK-2 inhibitor, drawing insights from long-term clinical trial data.
Linda Stein-Gold, MD, Mona Shahriari, MD, and Micheal Cameron, MD, FAAD explore emerging oral treatments for the management of plaque psoriasis, emphasizing the novelty of TYK-2 inhibition. They discuss the unique POETYK trial design, stressing the importance of the inclusion of an active control arm. Lastly, they highlight the clinical efficacy of this novel treatment MOA.
An expert in dermatology reviews the case of a 10-year-old male with segmental vitiligo, shedding light on the panel's gaps in understanding this complex condition. The conversation explores the treatment challenges and the emotional impact on patients, particularly those of Asian or Indian descent.
Karan Lal DO, MS, FAAD presents the case of a 51-year-old African American male with vitiligo, exploring insurance challenges, treatment options such as topical ruxolitinib, Excimer, and phototherapy, and strategies for setting and managing patient treatment response expectations.
An expert in dermatology presents the case of a 23-year-old male patient presenting with unstable vitiligo. He delves into treatment options available for managing this condition, shedding light on the nuances and optimal scenarios for each therapeutic agent.
James Song, MD, FAAD, presents the case of a 14-year-old male patient seeking vitiligo treatment. He emphasizes the significance of addressing mental health concerns alongside managing the physical symptoms of this condition. He further discusses possible approaches to treat the patient's depigmented patches, particularly considering that this patient was diagnosed with segmental vitiligo.
Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options. She also reviews the significance of patient assistance programs in facilitating patient access to and affordability of pharmaceutical therapies.
Tina Bhutani-Jacques, MD, presents the case of a 28-year old male with atopic dermatits, wherein the patient attributes his flares to his housing conditions. She discusses the role of patient counseling, shared decision making, and sustained disease control in the management of patients suffering from this condition.
Experts in dermatology share insights on considering the location's impact in treating plaque psoriasis, focusing on challenges with scalp involvement and addressing limitations with topical therapies.
Lisa Swanson, MD, FAAD and Robert J. Casquejo, PA-C highlight the impact of plaque psoriasis on both moderate and mild patients, emphasizing the importance of addressing these concerns in patient care.
An expert in skin condition management discusses the case of a 13-year-old male with a prolonged history of AD and early-onset food allergies. Emphasizing the challenges of the steroid treatment cycle, the expert provides insights into integrating parental preferences for "natural" agents alongside effective pharmaceutical options. Additionally, the discussion explores strategies for communicating treatment mechanisms to patients and fostering collaborative engagement in the treatment selection process.
TJ Chao, MPAS, PA-C, examines the case of an 18-year-old female with persistent AD, wherein the patient attributes her flares to her housing conditions. He discusses her treatment plan and addresses the challenges posed by red face syndrome induced by dupilumab, while commenting on how the panel managed patient expectations, treatment preferences, and sustained disease control.
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the newer treatments in AD, highlighting the positive impact these agents have had in managing the disease.
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the current treatment landscape of atopic dermatitis (AD), as well as key factors when selecting treatment for patients with the disease.
Dr Lal, an expert in dermatology, presents the case of a 45-year-old female with a history of childhood AD marked by severe symptoms. He recaps a panel conversation on the approach to treatment, emphasizing the importance of initiating effective and long-lasting treatment options for optimal relief.
Karan Lal, DO, MS, FAAD, discusses a case involving a 4-year-old male with atopic dermatitis, covering FDA-approved treatments for this age group, strategies for tapering and stopping treatment, the impact of the atopic march, and challenges with treatment prior authorizations.
An expert in the management of skin conditions provides an overview of a 20-year-old male diagnosed with atopic dermatitis, discussing key insights from a round table discussion. The conversation focused on effective management strategies, best practices for prior authorization approvals, and the significance of treatment vehicles.
Monica Harilall, PA-C, MMS, delves into the case of an 18-year-old female with atopic dermatitis, highlighting the challenges in managing adolescent patients who are self-conscious about their condition and seek rapid results. The discussion explores effective ways to communicate treatment mechanisms to patients and engage them collaboratively in the treatment selection process.
Benjamin Lockshin, MD, FAAD, summarizes the panel's best practices for improving patient education on the risks and benefits of vitiligo treatment. He underscores the importance of establishing and managing expectations for treatment response.
An expert in dermatology discusses the case of an active 71-year-old female who spends considerable time outdoors. The expert summarizes the panel's recommendations for counseling the patient on the benefits of treatment compliance and the use of sun-sparing products to enhance her quality of life and treatment response.
Benjamin Lockshin, MD, FAAD, summarizes key points from a panel discussion on the utilization of topical treatments in vitiligo. The first case revolves a 31-year-old woman with distressing depigmentation and highlights the panel's treatment approach to the management of this condition in difficult to treat areas.
An expert in dermatology discusses the case of an active 62-year-old female, who is self-conscious about her condition, and explores how the panel would advise her to maintain her outdoor lifestyle while discussing effective topical treatments.
Heather C Woolery-Lloyd, MD, discusses a 23-year-old woman with vitiligo vulgaris affecting 75% of her face, including complete depigmentation. She explores the panel’s response to managing progressive disease and its impact on the patient's quality of life.
Dr Darrel Rigel provides insights into cutting-edge photoprotection strategies, emphasizing the specific considerations for skin of color patients and the critical role of sunscreen in preventive dermatology.
Darrel Rigel, MD, MS, sheds light on the rationale behind broad-spectrum sunscreens, emphasizing the imperative protection against UV radiation and the significance of both organic and inorganic sunscreen compounds.
Saranya Wyles, MD, PhD, offers guidance on integrating advanced skincare technologies into their practices and the importance of staying updated through events like the Science of Skincare summit.
An expert in dermatology delves into the latest breakthroughs in antioxidants' role in anti-aging and receive expert guidance on seamlessly integrating these innovative approaches into your daily skincare regimen.
Saranya Wyles, MD, PhD, explores the science behind successful skincare products, focusing on key ingredients like retinoids and alpha hydroxy acids and their role in effective formulations across OTC and prescription products.
Dr Omar Noor delves into the complexities of boxed warnings tied to JAK inhibitors, contrasting their presence in systemic forms with the absence in the oral version of topical ruxolitinib, and discusses the potential impact on dialogues with both patients and fellow healthcare providers. He further underscores the pivotal role of long-standing safety data in building provider confidence in a treatment.
Omar Noor, MD, FAAD, discusses the critical role of patient education and transparent communication in the context of treating individuals with atopic dermatitis. He emphasizes the significance of cultivating trust in patient-provider relationships, explores the potential necessity of shifting the treatment paradigm, and addresses the implications of treatment interruptions or transitions in the long-term management of this condition, all while considering the crucial aspect of access to care.
